Singapore, March 12 -- Hong Kong-based CK Life Sciences has announced the establishment of Sequencio Therapeutics, a wholly-owned subsidiary dedicated to advancing the company's therapeutic cancer vaccine portfolio.Sequencio Therapeutics has been established to consolidate CK Life Sciences' therapeutic cancer vaccine research and development portfolio under a dedicated organisation, reflecting the company's strategic focus on this emerging class of cancer immunotherapy. The subsidiary is focused on the development of therapeutic cancer vaccines designed to train a patient's own immune system to achieve durable, long-term remission with a favourable safety profile, addressing key limitations of current standard-of-care therapies.

The esta...